Staidson Beijing Biopharma (300204) — Financial Flexibility Index
Staidson Beijing Biopharma (300204) has a Financial Flexibility Index of -0.06x as of September 2025. Free cash flow of CN¥-23.52 Million (operating CF CN¥-39.18 Million minus capex CN¥15.66 Million) represents 0% of total liabilities (CN¥404.22 Million). Also explore Staidson Beijing Biopharma equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Staidson Beijing Biopharma Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Staidson Beijing Biopharma across 19 annual periods. Check Staidson Beijing Biopharma PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Staidson Beijing Biopharma (2007–2025)
Year-by-year free cash flow to debt coverage for Staidson Beijing Biopharma. For the full company profile including market capitalisation, see Staidson Beijing Biopharma (300204) total market value.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.11x | CN¥-49.05 Million | CN¥-125.68 Million | CN¥459.48 Million | ▲ +38.1% |
| 2024 | -0.17x | CN¥-40.16 Million | CN¥-63.68 Million | CN¥232.85 Million | ▲ +72.5% |
| 2023 | -0.63x | CN¥-195.32 Million | CN¥-227.47 Million | CN¥311.55 Million | ▼ -66.1% |
| 2022 | -0.38x | CN¥-119.09 Million | CN¥-175.60 Million | CN¥315.45 Million | ▲ +1.5% |
| 2021 | -0.38x | CN¥-105.83 Million | CN¥-162.07 Million | CN¥276.25 Million | ▼ -56.6% |
| 2020 | -0.24x | CN¥-65.73 Million | CN¥-114.60 Million | CN¥268.70 Million | ▼ -153.3% |
| 2019 | 0.46x | CN¥104.25 Million | CN¥44.34 Million | CN¥227.18 Million | ▼ -44.6% |
| 2018 | 0.83x | CN¥260.54 Million | CN¥165.08 Million | CN¥314.30 Million | ▲ +8.5% |
| 2017 | 0.76x | CN¥320.19 Million | CN¥273.64 Million | CN¥419.14 Million | ▲ +38.2% |
| 2016 | 0.55x | CN¥239.00 Million | CN¥212.55 Million | CN¥432.32 Million | ▼ -16.1% |
| 2015 | 0.66x | CN¥254.96 Million | CN¥231.01 Million | CN¥387.06 Million | ▼ -11.4% |
| 2014 | 0.74x | CN¥221.32 Million | CN¥206.85 Million | CN¥297.54 Million | ▲ +41.4% |
| 2013 | 0.53x | CN¥134.39 Million | CN¥111.36 Million | CN¥255.47 Million | ▼ -32.2% |
| 2012 | 0.78x | CN¥149.07 Million | CN¥90.19 Million | CN¥192.15 Million | ▼ -78.6% |
| 2011 | 3.62x | CN¥171.36 Million | CN¥87.01 Million | CN¥47.32 Million | ▲ +144.4% |
| 2010 | 1.48x | CN¥146.15 Million | CN¥63.91 Million | CN¥98.66 Million | ▼ -22.6% |
| 2009 | 1.91x | CN¥55.56 Million | CN¥42.37 Million | CN¥29.03 Million | ▲ +69.4% |
| 2008 | 1.13x | CN¥33.03 Million | CN¥16.23 Million | CN¥29.25 Million | ▲ +849.6% |
| 2007 | 0.12x | CN¥5.75 Million | CN¥5.41 Million | CN¥48.35 Million | — |